Loss of c-Jun N-terminal Kinase 1 and 2 Function in Liver Epithelial Cells Triggers Biliary Hyperproliferation Resembling Cholangiocarcinoma
Related Experiment Video
Updated: Dec 19, 2025

The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury
Published on: October 21, 2017
Francisco Javier Cubero1,2,3, Mohamed Ramadan Mohamed1,4, Marius M Woitok1
1Department of Internal Medicine III University Hospital RWTH Aachen Aachen Germany.
Abstract:
Targeted inhibition of the c-Jun N-terminal kinases (JNKs) has shown therapeutic potential in intrahepatic cholangiocarcinoma (CCA)-related tumorigenesis. However, the cell-type-specific role and mechanisms triggered by JNK in liver parenchymal cells during CCA remain largely unknown. Here, we aimed to investigate the relevance of JNK1 and JNK2 function in hepatocytes in two different models of experimental carcinogenesis, the dethylnitrosamine (DEN) model and in nuclear factor kappa B essential modulator (NEMO)hepatocyte-specific knockout (Δhepa) mice, focusing on liver damage, cell death, compensatory proliferation, fibrogenesis, and tumor development. Moreover, regulation of essential genes was assessed by reverse transcription polymerase chain reaction, immunoblottings, and immunostainings. Additionally, specific Jnk2 inhibition in hepatocytes of NEMOΔhepa/JNK1Δhepa mice was performed using small interfering (si) RNA (siJnk2) nanodelivery. Finally, active signaling pathways were blocked using specific inhibitors. Compound deletion of Jnk1 and Jnk2 in hepatocytes diminished hepatocellular carcinoma (HCC) in both the DEN model and in NEMOΔhepa mice but in contrast caused massive proliferation of the biliary ducts. Indeed, Jnk1/2 deficiency in hepatocytes of NEMOΔhepa (NEMOΔhepa/JNKΔhepa) animals caused elevated fibrosis, increased apoptosis, increased compensatory proliferation, and elevated inflammatory cytokines expression but reduced HCC. Furthermore, siJnk2 treatment in NEMOΔhepa/JNK1Δhepa mice recapitulated the phenotype of NEMOΔhepa/JNKΔhepa mice. Next, we sought to investigate the impact of molecular pathways in response to compound JNK deficiency in NEMOΔhepa mice. We found that NEMOΔhepa/JNKΔhepa livers exhibited overexpression of the interleukin-6/signal transducer and activator of transcription 3 pathway in addition to epidermal growth factor receptor (EGFR)-rapidly accelerated fibrosarcoma (Raf)-mitogen-activated protein kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) cascade. The functional relevance was tested by administering lapatinib, which is a dual tyrosine kinase inhibitor of erythroblastic oncogene B-2 (ErbB2) and EGFR signaling, to NEMOΔhepa/JNKΔhepa mice. Lapatinib effectively inhibited cystogenesis, improved transaminases, and effectively blocked EGFR-Raf-MEK-ERK signaling. Conclusion: We define a novel function of JNK1/2 in cholangiocyte hyperproliferation. This opens new therapeutic avenues devised to inhibit pathways of cholangiocarcinogenesis.
Insights
Targeting c-Jun N-terminal kinases (JNKs) in hepatocytes reduced liver cancer but increased biliary duct proliferation. Inhibiting JNK1/2 in liver cells offers new therapeutic strategies for cholangiocarcinoma by targeting specific signaling pathways.
Area of Science:
- Hepatology and Cancer Biology
- Molecular mechanisms of liver carcinogenesis
Background:
- Targeted inhibition of c-Jun N-terminal kinases (JNKs) shows therapeutic promise for intrahepatic cholangiocarcinoma (CCA).
- The specific role of JNK in liver parenchymal cells during CCA development is not well understood.
Purpose of the Study:
- To investigate the function of JNK1 and JNK2 in hepatocytes during experimental liver carcinogenesis.
- To elucidate the mechanisms underlying JNK's role in liver damage, cell death, proliferation, fibrogenesis, and tumor development in CCA.
Main Methods:
- Utilized diethylnitrosamine (DEN) and nuclear factor kappa B essential modulator (NEMO) hepatocyte-specific knockout (NEMOΔhepa) mouse models.
- Assessed gene regulation via reverse transcription polymerase chain reaction, immunoblotting, and immunostaining.
- Employed small interfering RNA (siRNA) for Jnk2 inhibition and specific inhibitors for signaling pathways.
Main Results:
- Compound deletion of JNK1 and JNK2 in hepatocytes reduced hepatocellular carcinoma (HCC) but caused biliary duct hyperplasia.
- JNK1/2 deficiency in hepatocytes led to increased fibrosis, apoptosis, compensatory proliferation, and inflammatory cytokines, while reducing HCC.
- Inhibition of the interleukin-6/STAT3 and EGFR-Raf-MEK-ERK pathways with lapatinib ameliorated cystogenesis and improved liver function.
Conclusions:
- JNK1/2 play a critical role in regulating hepatocyte function during carcinogenesis, with dual effects on tumor suppression and biliary proliferation.
- JNK deficiency in hepatocytes activates pro-fibrotic and pro-inflammatory pathways, including IL-6/STAT3 and EGFR signaling.
- Targeting JNK and associated signaling pathways presents a novel therapeutic strategy for cholangiocarcinoma.
Related Concept Videos
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
MAPK Signaling Cascades
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
Mitogens and the Cell Cycle
Cell Specific Gene Expression

